Head and Neck Cancer – Analysis and Management

166
0
Head Neck Cancer 1

Up until the present, there have been no predictive biomarkers or indicators for guiding HNSCC treatment. A survey report on precision medicine entitled, “Global Precision Medicine Market : Analysis and Forecast, 2017–2026” from BIS Research registered $43.59 billion in 2016. It is estimated to reach $141.70 billion by 2026, with an annual growth rate of 11.23%. The Personalized Medicine Coalition for diagnostic and targeted agents was $25 billion in 2015. 

“On a thumb rule, 30% of newly Cancer screened cases would account for HNSCC, the majority of men affected by it.”

Dr. Hemantkumar Nemade,Consultant Head and Neck, OncologistBasavatarakam Indo-AmericanCancer Hospital, Hyderabad

The biomarkers for precision medicine drugs (in numbers) were 5 in 2008 and went up to 132 in 2016. According to a survey by the Tufts Centre for Drug Development, 42% of drugs are in the pipeline plan and will be considered soon. Global investments in the next 5 years are likely to increase by 33% for precision medicine drugs, and immunotherapy drugs. There is a surge in the global market, where the growth was $108 billion in 2016 and is nearly estimated to be $200 billion . . .

This exclusive content is reserved for our valued members. Kindly log in or sign up to enjoy full access and delve into the complete article.
Priya Subramani
WRITTEN BY

Priya Subramani

A post graduate in Nanotechnology, seamlessly integrates her expertise in engineering and research to craft compelling narratives that bridge the realms of science and technology, enlightening readers with her captivating writing.